ACH

SEC Filing Summary: Owens & Minor, Inc. (10-Q)

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for Owens & Minor, Inc., a medical supply distributor, for the period ended March 31, 2009. The company exited its direct-to-consumer (DTC) distribution business in January 2009, which is now reported as discontinued operations. The results of continuing operations reflect the integration of the acquired acute-care distribution business of The Burrows Company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 12.8% ($221.3 million) year-over-year. Approximately 70% of this growth is attributed to the Burrows acquisition and new business, with the remainder from existing accounts.
• Margin Compression: Gross margin percentage declined 43 basis points to 9.42%. This was driven by a $4.4 million revenue deferral related to performance-based contracts and supplier price increases that were 60% higher than in Q1 2008. The LIFO provision increased by $6.0 million to $16.4 million.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose $16.4 million to $139.4 million, primarily due to integration costs for the Burrows business (salaries, occupancy, freight, and transition expenses).
• Discontinued Operations: The company recorded a net loss of $8.4 million from discontinued operations in Q1 2009, compared to income of $0.2 million in Q1 2008. This loss includes charges for exiting the DTC business, partially offset by a $3.2 million gain on the sale of DTC assets.
• Debt Reduction: The company significantly reduced its revolving credit facility borrowings by $146.5 million during the quarter, utilizing cash from operations and proceeds from the DTC divestiture.

Guidance, Outlook, and Risks

Management Commentary: Management noted that operating earnings were negatively affected by the costs of integrating the Burrows acquisition. The company expects its available financing sources to be sufficient for working capital and strategic growth. The effective interest rate on borrowings decreased to 6.0% in Q1 2009 from 6.9% in Q1 2008.

Risks and Contingencies:

• Contractual Obligations: The company has $36.0 million in contingent obligations related to customer performance targets. If targets are not met, $4.3 million would be due in 2010 and $31.7 million in 2011.
• Regulatory Review: The state of California is reviewing business relocation incentives, which could result in a cash payment of up to $0.8 million or a receipt of up to $4.5 million.
• Market Risks: The company faces risks related to supplier price volatility, customer creditworthiness, and changes in healthcare regulations. A hypothetical 100 basis point increase in interest rates would reduce pre-tax earnings by approximately $0.1 million per year for every $10 million of outstanding borrowings.

Investor Verification Checklist

• Discontinued Operations Impact: Verify the final settlement of the DTC business exit charges and the realization of the $3.2 million asset sale gain.
• Revenue Deferral: Monitor the recognition of the $4.4 million deferred revenue related to performance-based contracts in future quarters.
• Integration Costs: Assess whether SG&A expenses related to the Burrows integration are stabilizing or expected to persist.
• LIFO Provision: Track the impact of supplier price increases on the LIFO reserve and gross margins in subsequent periods.
• Contingent Liabilities: Review the status of the $36.0 million in contractual performance obligations and the California tax incentive review.